WINT

Windtree Therapeutics (WINT)

Windtree Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:WINT

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/16	22 : 00	GlobeNewswire Inc.	Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference	NASDAQ:WINT	Windtree Therapeutics Inc
2024/12/09	22 : 00	GlobeNewswire Inc.	Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia	NASDAQ:WINT	Windtree Therapeutics Inc
2024/12/05	21 : 12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/12/04	22 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/12/04	22 : 00	GlobeNewswire Inc.	Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction	NASDAQ:WINT	Windtree Therapeutics Inc
2024/11/28	06 : 43	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/11/28	06 : 05	GlobeNewswire Inc.	Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates	NASDAQ:WINT	Windtree Therapeutics Inc
2024/11/14	22 : 53	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:WINT	Windtree Therapeutics Inc
2024/11/14	22 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/11/14	22 : 00	GlobeNewswire Inc.	Windtree Announces Leadership Transition Plan With Industry Veterans	NASDAQ:WINT	Windtree Therapeutics Inc
2024/11/04	22 : 00	GlobeNewswire Inc.	Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong	NASDAQ:WINT	Windtree Therapeutics Inc
2024/10/30	21 : 00	GlobeNewswire Inc.	Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3	NASDAQ:WINT	Windtree Therapeutics Inc
2024/10/23	21 : 00	GlobeNewswire Inc.	Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World	NASDAQ:WINT	Windtree Therapeutics Inc
2024/10/21	21 : 00	GlobeNewswire Inc.	Windtree To Present at the ThinkEquity Conference on October 30th	NASDAQ:WINT	Windtree Therapeutics Inc
2024/10/17	21 : 15	GlobeNewswire Inc.	Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan	NASDAQ:WINT	Windtree Therapeutics Inc
2024/10/09	21 : 00	GlobeNewswire Inc.	Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design	NASDAQ:WINT	Windtree Therapeutics Inc
2024/10/09	20 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/30	21 : 15	GlobeNewswire Inc.	Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/27	05 : 05	GlobeNewswire Inc.	Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/25	21 : 15	GlobeNewswire Inc.	Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/25	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/25	06 : 21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/04	21 : 00	GlobeNewswire Inc.	Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/04	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/04	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/03	22 : 10	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/03	22 : 09	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/03	20 : 26	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:WINT	Windtree Therapeutics Inc
2024/09/03	20 : 22	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:WINT	Windtree Therapeutics Inc
2024/08/24	05 : 15	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:WINT	Windtree Therapeutics Inc